Janssen publicizes more Darzalex data

Genmab’s US partner Janssen has presented new data on the effect of the cancer drug Darzalex.

Photo: Tuala Hjarnø / Genmab / PR

On Friday, Genmab’s partner released more data from the phase III MAIA study with Darzalex (daratumumab). This data should not have a major effect on the Genmab share price. 

"From an interest rate perspective, you shouldn’t put too much into it. However, this says something about the effect and responses connected with Darzalex," states Sydbank Chief Equity Analyst Søren Løntoft Hansen. 

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs